Central European Time

Aperam publishes Convening Notice for Annual General Meeting of shareholders

Retrieved on: 
Wednesday, April 10, 2024
Central European Time, Mass meeting, Aperam, Security (finance)

Luxembourg March 29, 2024 (07:00 CET) - Aperam announces the publication of the convening notice for its Annual General Meeting of shareholders (“the General Meeting”), which will be held on Tuesday 30 April 2024 at 11:00 hours at Luxembourg time at 24-26, boulevard d'Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.

Key Points: 
  • Luxembourg March 29, 2024 (07:00 CET) - Aperam announces the publication of the convening notice for its Annual General Meeting of shareholders (“the General Meeting”), which will be held on Tuesday 30 April 2024 at 11:00 hours at Luxembourg time at 24-26, boulevard d'Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.
  • The Aperam shareholders entitled to vote at the General Meeting will be those who are shareholders on the record date of 16 April 2024 at midnight (24:00 hours) Central European Time.

STMicroelectronics Announces Timing for First Quarter 2024 Earnings Release and Conference Call

Retrieved on: 
Thursday, April 4, 2024
Central European Time, Electronics, STM

Geneva – April 4, 2024 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release first quarter 2024 earnings before the opening of trading on the European Stock Exchanges on April 25, 2024.

Key Points: 
  • Geneva – April 4, 2024 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release first quarter 2024 earnings before the opening of trading on the European Stock Exchanges on April 25, 2024.
  • STMicroelectronics will conduct a conference call with analysts, investors and reporters to discuss its first quarter 2024 financial results and current business outlook on April 25, 2024 at 9:30 a.m. Central European Time (CET) / 3:30 a.m. U.S. Eastern Time (ET).
  • A live webcast (listen-only mode) of the conference call will be accessible at ST’s website, http://investors.st.com , and will be available for replay until May 10, 2024.

Fortuna to present at the Gold Forum Europe 2024 in Zürich, Switzerland

Retrieved on: 
Monday, March 25, 2024
FSM, Central European Time, TSX, FVI

VANCOUVER, British Columbia, March 25, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce that it will be attending Gold Forum Europe 2024 , which is being held at the Park Hyatt in Zürich, Switzerland, from April 8 to 10, 2024.

Key Points: 
  • VANCOUVER, British Columbia, March 25, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce that it will be attending Gold Forum Europe 2024 , which is being held at the Park Hyatt in Zürich, Switzerland, from April 8 to 10, 2024.
  • Jorge A. Ganoza, President, Chief Executive Officer, and co-founder of Fortuna, will be presenting on Tuesday, April 9 at 2:30 p.m. Central European Time in Ballroom 3.

Coeur to Present at Gold Forum Europe

Retrieved on: 
Thursday, April 4, 2024
Natural Resources, Other Natural Resources, Mining, Minerals, CDE, Senior, Central European Time

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) announced today that Senior Vice President and Chief Financial Officer Thomas S. Whelan will present at Gold Forum Europe in Zurich, Switzerland on Wednesday, April 10, 2024 at 1:10 p.m. Central European Time.

Key Points: 
  • Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) announced today that Senior Vice President and Chief Financial Officer Thomas S. Whelan will present at Gold Forum Europe in Zurich, Switzerland on Wednesday, April 10, 2024 at 1:10 p.m. Central European Time.
  • Gold Forum Europe is an invitation-only investment conference.
  • Presentation materials will be made available on the Company’s website at www.coeur.com .

Esker 2023 Annual Results

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Payments, Data Management, Business, Security, Technology, Finance, Automation, Central European Time, Software as a service, Growth, ARR, FY, Acceleration, Travel, Policy, Acquisition, Market Dojo, Bank statement, Esker, Publication, Investment, Treasury, Marketing, Pharmaceutical industry

Esker 2023 sales revenue amounted to 178.6 million euros, a 12% increase over 2022 (14% based on constant exchange rates).

Key Points: 
  • Esker 2023 sales revenue amounted to 178.6 million euros, a 12% increase over 2022 (14% based on constant exchange rates).
  • The annual recurring value (ARR) of new contracts signed during 2023 increased by 23% based on constant exchange rates compared to 2022.
  • As announced at publication of the Q3 2023 sales results, the increase in sales costs linked to the acceleration in bookings impacts 2023 operating income for 3.5 million euros, or 1.9% of sales.
  • As anticipated at the time of the half-year and Q3 2023 results, Esker’s operating profitability for 2023 fell by 3.5 points to 10% of sales revenue.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SMMT, Sun, EGFR, Central European Time, ELCC, NSCLC, Anaplastic lymphoma kinase, Drug, HKEX, Safety, Phase, Summit, TKI, Time in Europe, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.
  • Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time.
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • These patients were enrolled in either AK112-202 (NCT04900363), in which ivonescimab is delivered as monotherapy, or AK112-201 (NCT04736823), in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC.

JGIF: Solving Global Social Challenges Showcasing Japan's Start-ups to the World

Retrieved on: 
Monday, March 11, 2024
Central European, Yūrakuchō Station, Central European Time, Diplomatic mission, Commentator, Silver, Byte, PBMC, Sector, Commerce, Snack, Multimedia, Physical, Flour

Participating Commentators' Countries of Origin: Spain, Germany, the Netherlands, USA, Japan, among others.

Key Points: 
  • Participating Commentators' Countries of Origin: Spain, Germany, the Netherlands, USA, Japan, among others.
  • Tickets: ¥1,500 for on-site participants (includes snacks and drinks for networking event); free for online participants.
  • Topic: How Can Social Innovators in Japan Shine on a Global Stage?
  • - Exploring Japan as a Pioneer Nation in Global Challenges: Unveiling the Sectors Capturing Worldwide Interest
    Light refreshments and soft drinks will be served, and participants will have an opportunity to chat with each other.

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, MSK, Forecasting, Constant, Sophia Genetics, Pension, Average cost, Growth, Table, NGS, Book of Wisdom, DASA, Liquid biopsy, COVID-19, Eastern Time Zone, Recombinant DNA, HRD, COVID, Neoplasm, Patient, Public expenditure, Platform, FY, Genomics, Microsoft, Research, GENETICS, Cancer, Central European Time, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2023 results, and financial guidance for the full year 2024 on Tuesday, March 5, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
  • These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans.

Orion S.A. Announces its 2024 Annual General Meeting Date and Record Date

Retrieved on: 
Thursday, February 29, 2024
Chemicals, Plastics, Other Manufacturing, Manufacturing, OEC, Exercise, Municipality, Communication, Central European Time

Orion S.A. (NYSE:OEC), a specialty chemical company, today announced that it will hold its 2024 annual general meeting of shareholders on Thursday, June 20, 2024, at 2:00 pm Central European Time at the company’s office, located at 6, Route de Trèves, L-2633 Senningerberg (Municipality of Niederanven), Grand Duchy of Luxembourg.

Key Points: 
  • Orion S.A. (NYSE:OEC), a specialty chemical company, today announced that it will hold its 2024 annual general meeting of shareholders on Thursday, June 20, 2024, at 2:00 pm Central European Time at the company’s office, located at 6, Route de Trèves, L-2633 Senningerberg (Municipality of Niederanven), Grand Duchy of Luxembourg.
  • The company also set its record date for the admission of the company’s shareholders to its annual general meeting to April 26, 2024, at 11:59 pm Central European Time.
  • The company will make it possible to attend its annual general meeting virtually and to exercise shareholder rights in advance of the meeting by means of remote communication.